Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine, Business Practice

Breaking the Bottleneck of Affordability

Advances in cell and gene therapies offer the potential to transform medicine. But current pricing structures are unsustainable – and they are severely limiting the introduction of new, potentially life-changing or life-saving therapeutics. 

Though research and development in this sector is moving at an impressive rate, the complexities of scale for growing, sourcing and transporting cells and other components of cell and gene therapies are evident – and this is clearly feeding into costs.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Vered Caplan

Cheif Executive Officer, Orgenesis Inc., USA.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register